October 5, 2023 in Kineta Press Release

Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  SEATTLE, Oct. 05, 2023 -- Kineta, Inc. (Nasdaq: KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that add ...

Read More
October 4, 2023 in Kineta Press Release

Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

Preclinical data highlights CD27's mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors   SEATTLE, Oct. 04, 2023 -- Kineta ...

Read More
October 3, 2023 in Kineta Press Release

Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial

  Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level >90% VISTA Receptor Occupancy Observed in the 30 mg Dos ...

Read More
September 25, 2023 in Kineta Press Release

Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

  SEATTLE, Sept. 25, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistan ...

Read More